Asset Details
Do you wish to reserve the book?
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702
Do you wish to request the book?
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702
2024
Overview
•Those assigned female at birth experience more reactogenicity.•Most symptoms are mild.•Pain and/or tenderness symptom common in both vaccine and placebo groups.
Reactogenicity informs vaccine safety, and may influence vaccine uptake. We evaluated factors associated with reactogenicity in HVTN 702, a typical HIV vaccine efficacy trial with multiple doses and products.
HVTN 702, a phase 2b/3 double-blind placebo-controlled trial, randomized 5404 African participants aged 18–35 years without HIV to placebo, or ALVAC-HIV (vCP2438) at months 0, 1 and ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, 12 and 18. Using multivariate logistic regression, we evaluated associations between reactogenicity with clinical, sociodemographic and laboratory variables.
More vaccine than placebo-recipients reported local symptoms (all p < 0.001), arthralgia (p = 0.008), chills (p = 0.012) and myalgia (p < 0.001). Reactogenicity was associated with female sex at birth (ORv = 2.50, ORp = 1.81, both p < 0.001) and geographic region. Amongst vaccine-recipients, each year of age was associated with 3 % increase in reactogenicity (OR = 1.03, p = 0.002).
Vaccine receipt, female sex at birth, older age, and region may affect reactogenicity.
Publisher
Elsevier Ltd,Elsevier Limited,Elsevier Science
Subject
Acquired immune deficiency syndrome
/ Adult
/ Age
/ AIDS
/ AIDS Vaccines - administration & dosage
/ AIDS Vaccines - adverse effects
/ Chills
/ Female
/ Females
/ Fever
/ Gender
/ HIV
/ HIV Infections - prevention & control
/ Human immunodeficiency virus
/ Humans
/ Male
/ Myalgia
/ Pain
/ Placebos
/ Region
/ Sex
/ Sexually transmitted diseases
/ STD
/ Vaccine
/ Vaccines
